Breast Cancer Clinical Trial
Official title:
Face-to-face Interviews or Written Self-report Questionnaires: The Distress-barometer as a Screening Instrument for Psychosocial Complaints in Patients With Breast Cancer
Breast cancer is the most prevalent cancer among women worldwide [1]. 5 years after
diagnosis, up to 87% survives. A substantial group of these survivors report reduced
physical, psycho social and cognitive functioning. Therefore, it is increasingly important to
screen for distress, both during and after treatment. The Distress Barometer (DB) is a valid,
short screening instrument, used to detect elevated levels of distress in patients with
cancer. It can be used either in a self-report questionnaire or in an interview format.
Although the DB is used in different ways, it remains unclear whether both assessment methods
would generate similar results, and which format is most suitable to represent the actual
level of distress. Existing literature on the DB lacks a systematic description of the
relationship between the method of assessment and the patients' responses. This study
questions whether the written and interview variants of the DB reveal different results in
the same patients with breast cancer.
Objective:
This study questions whether the written and interview variants of the DB reveal different
results in the same patients with breast cancer.
Participants:
Participants were female breast cancer patients who received their diagnosis about three
years before the study. Thirty patients received follow-up care in Ziekenhuis Oost-Limburg
(ZOL). An additional twenty-nine patients were included in the KLIMOP-study and recruited in
three Belgian hospitals (ZOL, University Hospital Leuven, Jessa Ziekenhuis). Patients were
included through either clinical practice or the KLIMOP-study. All participating patients had
to be able to read and understand Dutch and signed informed consent. In total, 59 patients
took part in the study.
Data collection:
Two weeks after the face-to-face interview, patients with breast cancer will be provided with
a written version of the DB questionnaire together with a prepaid envelop in order to
evaluate the differences in written and oral versions of the DB.
Data management:
Data collection and data entries will be done by the PI and an assisting data manager. All
patient data will be coded and anonymized. All other authors will have full access to the
coded data (including statistical reports and tables) in the study and will be able to take
responsibility for the integrity of the data and the accuracy of the data analysis.
Statistical analysis A chi-square test, accuracy and kappa statistic were performed to
compare the dichotomized results of the DB between the interviews and questionnaires.
Furthermore, paired t-tests were applied to compare the mean scores coming from interview and
questionnaire for the CCS and for the DT.
Ethics:
This study is part of the ongoing KLIMOP-study and current clinical practice of ZOL. The
study was added in the KLIMOP-study through an amendment to the Medical Ethics Committee
S52097 / ML6279 (University Hospital Leuven) and a new study protocol was submitted to and
approved by the Medical Ethics Committee of ZOL 16/050U.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |